Clinical Trials Logo

Gynecologic Cancer clinical trials

View clinical trials related to Gynecologic Cancer.

Filter by:

NCT ID: NCT04544735 Suspended - Gynecologic Cancer Clinical Trials

Improving Women's Function After Pelvic Radiation

Start date: October 7, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to develop and test an intervention combining physical therapy (PT) and coping skills training to improve women's sexual function after pelvic radiation.

NCT ID: NCT04534075 Recruiting - Gynecologic Cancer Clinical Trials

Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial

FIDURA
Start date: September 2, 2020
Phase: Phase 3
Study type: Interventional

The investigators hypothesize that an increase in dietary fiber intake during radiation therapy may provide better long-term intestinal health for the cancer survivor. If the hypothesis is not correct, the increased intake may only mean an increase in acute side effects. All participants are advised to consume at least 16 g of dietary fiber/day via food. In addition, participants are invited to take capsules that together contain either 5.5 g of dietary fiber from psyllium husk or placebo.

NCT ID: NCT04530890 Recruiting - Breast Cancer Clinical Trials

Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer

Start date: January 20, 2021
Phase: N/A
Study type: Interventional

Circulating tumor DNA (ctDNA) offers the possibility of accessing the tumor genome from circulating blood through a simple blood test. It is currently used for diagnostic, prognostic and predictive purposes of response or resistance to oncological treatments. These advances in ctDNA have been made possible by major developments in molecular biology techniques in recent years, as the detection of ctDNA requires very sensitive techniques such as Next Generation Sequencing (NGS). CtDNA overcomes this problem of very limiting tumor heterogeneity during a solid biopsy. All of these applications make circulating DNA an increasingly essential tool in the management of cancer patients. The studies are currently in most cases on small numbers and are retrospective. In addition, exosomes are also a biomarker of the future that can also be detected in the bloodstream . Exosomes are nanovesicles 50 to 200 nm in diameter released into the extracellular environment via the endosomal pathway by fusion with the plasma membrane. They are very informative since they transport tumor genetic material in the form of DNA, mRNA and miRNA, but also adhesion proteins, immunostimulatory molecules and cytoskeleton, enzymes and Heats shock proteins ( HSP). The aim of the ADIGYN study is to set up a large prospective cohort to assess the diagnostic, prognostic and predictive impact of ctDNA and exosomes in digestive and gynecological / breast cancers. From the circulating DNA, we characterize the ActDNA on the molecular level thanks to the study of different point mutations usually used but also of new described mutations having a therapeutic impact and the search for other genetic alterations having an impact on the therapeutic strategy (such as microsatellite instability) or the study of exosomes and their composition. To assess resistance to oncological treatments, ctDNA will be analyzed at the start of treatment, during treatment, during progression and / or relapse and also during monitoring or treatment break

NCT ID: NCT04530019 Not yet recruiting - Gynecologic Cancer Clinical Trials

Brachytherapy Innovations in Gynecologic Cancer

Start date: July 2024
Phase:
Study type: Observational

In this pilot study, the investigators will test tools designed to more precisely identify, define and create a radiation treatment plan to tumor remnants as separate from fibrotic or normal tissue in a Magnetic Resonance (MR) simulator in the department of radiation oncology. The investigators will examine if this beneficial for tumor versus normal tissue delineation, will result in more precise tumor targeting with radiation in an efficient manner and whether there would be fewer toxicities.

NCT ID: NCT04512144 Recruiting - Quality of Life Clinical Trials

Mindfulness in Endometrial and Cervical Cancer

MECCA
Start date: July 25, 2020
Phase: N/A
Study type: Interventional

Patients with endometrial cancer who will be undergoing surgery or patients with cervical cancer who will be treated with chemoradiation will be randomized to utilize the Headspace smartphone application or not prior to their anticipated treatment.

NCT ID: NCT04503668 Terminated - Gynecologic Cancer Clinical Trials

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Start date: December 28, 2020
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.

NCT ID: NCT04498767 Recruiting - Pancreatic Cancer Clinical Trials

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

OligoRARE
Start date: June 10, 2021
Phase: N/A
Study type: Interventional

This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers. Patients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease. The primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.

NCT ID: NCT04474951 Recruiting - Breast Cancer Clinical Trials

Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies

GALENO 1
Start date: June 20, 2019
Phase: N/A
Study type: Interventional

The main purpose of this study is to evaluate the impact of food supplements (herbal remedies) on sign and symptoms induced by cancer therapies: Nettle will be administered for improvement of anemia and fatigue; Peppermint will be administered for improvement of nausea. Secondary aims of the trial are to evaluate the impact of these supplements on the quality of life and to evaluate their tolerability profile.

NCT ID: NCT04368130 Withdrawn - Ovarian Cancer Clinical Trials

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

SIGNAL
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.

NCT ID: NCT04362046 Recruiting - Endometrial Cancer Clinical Trials

Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia

FETCH
Start date: November 15, 2020
Phase: N/A
Study type: Interventional

This study protocol evaluates the use of hysteroscopic endomyometrial resection in women diagnosed with atypical endometrial hyperplasia or grade I endometrial cancer who have not responded to anti-hormone therapy. Patients in this study wish to preserve fertility.